Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: Experience from a pediatric case series

Journal of Chemotherapy

Volumn 24, Issue 4, 2012, Pages 243-244

  Ginocchio, Francesca ^a   Faraci, Maura ^a   Fioredda, Francesca ^a   Moroni, Cristina ^a   Caviglia, Ilaria ^a   Barabino, Paola ^a   Haupt, Riccardo ^a   Castagnola, Elio ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; TRIAZOLE;

ADOLESCENT; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; INVASIVE FUNGAL DISEASE; LETTER; LIVER TOXICITY; LOW BACK PAIN; MALE; MYCOSIS; PEDIATRICS; PRESCHOOL CHILD; PROPHYLAXIS; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; AMPHOTERICIN B; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; IMMUNOCOMPROMISED HOST; LIPOSOMES; LUNG DISEASES, FUNGAL; MALE; MYCOSES; TIME FACTORS;

EID: 84866263993     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000012     Document Type: Letter

References (14)

1. Cornely OA, Bohme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, et al. Risk factors for breakthrough invasive fungal infections during secondary prophylaxis. J Antimicrob Chemother. 2008;61:939-46.
2. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frêre P, et al. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant. 2011;46:709-18.
3. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondaryantifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother. 2008;61:734-42.
4. El Cheikh J. Secondary antifungal prophylaxis in hematopoietic stem cells transplantation (HSCT)/acute leukemia patients. Curr Infect Dis Rep. 2011;13:528-35.
5. De Paw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
6. Song A, Yang D, Huang Y, Jiang E, Yan Z, Wei J, et al. Secondary antifungal prophylaxis in hematological malignancies in a tertiary medical center. Int J Hematol. 2010;92:725-31.
7. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27-36
8. Brueggemann RJM, Allfenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agent. Clin Infect Dis. 2009;48:1441-58.
9. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res. 2000;17:1494-502.
10. Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, et al. Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. Antimicrob Agents Chemother. 2006;50:935-42.
11. Metha P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12:235-40.
12. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487-96.
13. El-Cheikh J, Faucher C, Furst S, Duran S, Berger P, Vey N, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cells transplantation. Bone Marrow Transplant. 2007;39:301-6.
14. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infections: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis. 2007;44:1289-97.